OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Alemtuzumab in a Large Real-Life Cohort: Interim Baseline Data of the TREAT-MS Study
Tjalf Ziemssen, Frank Hoffmann, Stephan Richter, et al.
Frontiers in Neurology (2021) Vol. 12
Open Access | Times Cited: 9
Tjalf Ziemssen, Frank Hoffmann, Stephan Richter, et al.
Frontiers in Neurology (2021) Vol. 12
Open Access | Times Cited: 9
Showing 9 citing articles:
High-Efficacy Therapies for Treatment-Naïve Individuals with Relapsing–Remitting Multiple Sclerosis
Léorah Freeman, Erin E. Longbrake, Patricia K. Coyle, et al.
CNS Drugs (2022) Vol. 36, Iss. 12, pp. 1285-1299
Open Access | Times Cited: 76
Léorah Freeman, Erin E. Longbrake, Patricia K. Coyle, et al.
CNS Drugs (2022) Vol. 36, Iss. 12, pp. 1285-1299
Open Access | Times Cited: 76
Long-term efficacy and safety of alemtuzumab in participants with highly active MS: TOPAZ clinical trial and interim analysis of TREAT-MS real-world study
Tjalf Ziemssen, Ann Bass, Bart Van Wijmeersch, et al.
Therapeutic Advances in Neurological Disorders (2025) Vol. 18
Open Access
Tjalf Ziemssen, Ann Bass, Bart Van Wijmeersch, et al.
Therapeutic Advances in Neurological Disorders (2025) Vol. 18
Open Access
Real-World Retrospective Analysis of Alemtuzumab Outcomes in Relapsing-Remitting Multiple Sclerosis: The LEMCAM Study
Lucienne Costa‐Frossard, Virginia Meca‐Lallana, Andrés Labiano-Fontcuberta, et al.
CNS Drugs (2024) Vol. 38, Iss. 3, pp. 231-238
Open Access | Times Cited: 3
Lucienne Costa‐Frossard, Virginia Meca‐Lallana, Andrés Labiano-Fontcuberta, et al.
CNS Drugs (2024) Vol. 38, Iss. 3, pp. 231-238
Open Access | Times Cited: 3
Alemtuzumab following natalizumab is more effective in adult-onset than paediatric-onset multiple sclerosis
Marco Puthenparampil, Marta Gaggiola, Alessandro Miscioscia, et al.
Therapeutic Advances in Neurological Disorders (2023) Vol. 16
Open Access | Times Cited: 7
Marco Puthenparampil, Marta Gaggiola, Alessandro Miscioscia, et al.
Therapeutic Advances in Neurological Disorders (2023) Vol. 16
Open Access | Times Cited: 7
Results of treatment with alemtuzumab in a Spanish cohort of patients with multiple sclerosis in the real world: The RealMS study
Sara Eichau, Rocío López Ruiz, M. Ruíz De Arcos, et al.
Frontiers in Neurology (2023) Vol. 14
Open Access | Times Cited: 6
Sara Eichau, Rocío López Ruiz, M. Ruíz De Arcos, et al.
Frontiers in Neurology (2023) Vol. 14
Open Access | Times Cited: 6
The Place of Immune Reconstitution Therapy in the Management of Relapsing Multiple Sclerosis in France: An Expert Consensus
de Sèze, Laurent Suchet, Claude Mékiès, et al.
Neurology and Therapy (2022) Vol. 12, Iss. 2, pp. 351-369
Open Access | Times Cited: 8
de Sèze, Laurent Suchet, Claude Mékiès, et al.
Neurology and Therapy (2022) Vol. 12, Iss. 2, pp. 351-369
Open Access | Times Cited: 8
Alemtuzumab treatment for multiple sclerosis in Austria: An observational long‐term outcome study
Tobias Moser, Fabian Foettinger, Wolfgang Hitzl, et al.
Annals of Clinical and Translational Neurology (2024) Vol. 11, Iss. 6, pp. 1442-1455
Open Access | Times Cited: 1
Tobias Moser, Fabian Foettinger, Wolfgang Hitzl, et al.
Annals of Clinical and Translational Neurology (2024) Vol. 11, Iss. 6, pp. 1442-1455
Open Access | Times Cited: 1
A real-life study of alemtuzumab in persons with multiple sclerosis: Kuwait's experience
Raed Alroughani, Malak AlMojel, Jasem Al–Hashel, et al.
Multiple Sclerosis and Related Disorders (2023) Vol. 74, pp. 104712-104712
Closed Access | Times Cited: 3
Raed Alroughani, Malak AlMojel, Jasem Al–Hashel, et al.
Multiple Sclerosis and Related Disorders (2023) Vol. 74, pp. 104712-104712
Closed Access | Times Cited: 3
Risk of secondary immune thrombocytopenia following alemtuzumab treatment for multiple sclerosis: a systematic review and meta-analysis
Yuying Sun, Zhimei Liu, Jianguo Yang, et al.
Frontiers in Neurology (2024) Vol. 15
Open Access
Yuying Sun, Zhimei Liu, Jianguo Yang, et al.
Frontiers in Neurology (2024) Vol. 15
Open Access
